

To view an archived recording of this presentation please click the following link:

https://youtu.be/V6-tpeY3SIM

Please scroll down this file to view a copy of the slides from the session.



Changes to Serological Testing of Lyme Disease

Samir Patel, Chief, Microbiology and Laboratory Sciences, Public Health Ontario

Richard Mather, Public Health Physician, Public Health Ontario

April 13, 2023

Public Health Ontario Rounds

Learning Objectives

By the end of this session, participants will be able to:

- Describe the epidemiology of Lyme disease in Ontario
- Identify the new Lyme disease testing method and how it compares to previous testing methods
- Interpret laboratory results using the new modified two-tier testing (MTTT) for detection of Lyme disease


Outline

- Epidemiology of Lyme disease in Ontario
- Clinical stages of Lyme disease
- Diagnostic testing for Lyme disease and changes to serological testing
- Implications for practice
- Case studies

Lyme Disease Overview

- Lyme disease is the most common tick-borne infection in Canada
- Vector-borne disease caused by infection with the spirochete bacteria *Borrelia burgdorferi* (in North America)
- B. burgdorferi is transmitted to humans in Ontario through the bite of an infected blacklegged tick (*Ixodes scapularis*) that has been attached for >24 hours

Blacklegged Tick Life-Cycle



Source: Ontario Agency for Health Protection and Promotion (Public Health Ontario). Technical report: Update on Lyme disease prevention and control. Second edition. Toronto, ON: Queen's Printer for Ontario; 2016. Available from:

nymph

larva

Source: Source: Health Quality Ontario. Clinical guidance document: management of tick bites and investigation of early localized Lyme disease. Toronto, ON: King's Printer for Ontario; 2023. Available from:

Lyme Disease Transmission


- Nymphal ticks are most likely to transmit *B. burgdorferi*:
 - Active in late spring + summer when humans are most often in areas where ticks live
 - Small in size so harder to detect when attached to a person





Source: Health Canada. Blacklegged (deer) ticks [Internet]. Ottawa, ON: Government of Canada; 2015 [cited 2023 Apr 13]. Figure 3; Figure 4. Available from:


Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW, Li X, Mead PS. Lyme borreliosis. Nat Rev Dis Primers. 2016;2:16090. Available from:



Source: Ontario Agency for Health Protection and Promotion (Public Health Ontario). Ontario Lyme disease map 2022 estimated risk areas [Internet]. Toronto, ON: Queen's Printer for Ontario; 2022 [cited 2023 Apr 06]. Available from:

Lyme Disease Cases in Ontario

Lyme disease rates and cases for all ages, for all sexes, in Ontario



🔽 Total cases 🛛 🔽 Total rates

Source: Ontario Agency for Health Protection and Promotion (Public Health Ontario). Infectious disease trends in Ontario [Internet]. Toronto, ON: King's Printer for Ontario; 2022 [cited 2023 Apr 6]. Available from:

Lyme Disease Clinical Manifestations

- Early localized
 - 3 to 30 days after an infected tick bite
- Early disseminated
 - 1-3 months after an infected tick bite
- Late disseminated
 - >3 months after an infected tick bite

Source: Government of Canada. Lyme disease: for health professionals [Internet]. Ottawa, ON: Government of Canada; 2022 [cited 2023 Apr 13]. Available from:

Early Localized Lyme Disease

- 3 to 30 days after tick bite (usually 7-14 days)
- Erythema migrans rash
 - Expanding rash >5 cm, occurs in 70-80% of infected patients
- Other potential signs + symptoms:
 - Fever, generalized arthralgia and myalgia, headache, lymphadenopathy



Source: Public Health Agency of Canada. Lyme disease: symptoms and treatment [Internet]. Ottawa, ON: Government of Canada; 2022 [cited 2023 Apr 13]. Available from:

Early Disseminated Lyme Disease

- Weeks to months after tick bite
- Fatigue and general weakness
- Multiple erythema migrans lesions
- Peripheral/central nervous system
 - Cranial nerve palsies (often 7th)
 - Meningitis or encephalitis
 - Subtle cognitive difficulties

Cardiac symptoms

- Atrioventricular (AV) node block
- Atrial fibrillation
- Myocarditis, pericarditis or endocarditis

Public Health Agency of Canada. Lyme disease: for health professionals [Internet]. Ottawa, ON: Government of Canada; 2022 [cited 2023 Apr 13]. Available from:

Late Disseminated Lyme Disease


- Weeks to months after the initial infection, late symptoms can occur if untreated, including:
- Musculoskeletal
 - Arthritis often monoarticular, usually involves large joints, especially the knee
 - Baker's cyst
- Neurological
 - Meningitis
 - Subacute mild encephalopathy, affecting memory + concentration
 - Polyneuropathy

Public Health Agency of Canada. Lyme disease: for health professionals [Internet]. Ottawa, ON: Government of Canada; 2022 [cited 2023 Apr 13]. Available from:

Lyme Disease Serological Testing

Current Testing Approach in Ontario

2-tier testing (Recommended by IDSA/CDC and CPHLN)



IDSA: Infectious Disease Society of America CDC: Centers for Disease Control CPHLN: Canadian Public Health Laboratory Network

Sensitivity of two-tier testing

Erythema migrans, acute phase	29-40%
(early localized disease)	


Erythema migrans, convalescence phase [‡]	29–78%
(early localized disease)	

Neurological involvement (early	87%
disseminated disease)	

Arthritis (late disseminated disease) 97%

Is there an alternative method that can be used to improve sensitivity or workflow?

Modified-two Tier-testing (MTTT)



Evaluation of Modified Two-Tiered Testing Algorithms for Lyme Disease Laboratory Diagnosis Using Well-Characterized Serum Samples



Adoracion Pegalajar-Jurado,^{a*} Martin E. Schriefer,^a Ryan J. Welch,^b Marc R. Couturier,^{b,c} Tiffany MacKenzie,^{d*} Rebecca J. Clark,^{a*} Laura V. Ashton,^a Mark J. Delorey,^a Claudia R. Molins^a




FIG 1 MTTT and STTT algorithms evaluated in this study.

Evaluation of Modified Two-Tiered Testing Algorithms for Lyme Disease Laboratory Diagnosis Using Well-Characterized Serum Samples

Adoracion Pegalajar-Jurado,^{a*} Martin E. Schriefer,^a Ryan J. Welch,^b Marc R. Couturier,^{b,c} Tiffany MacKenzie,^{d*} Rebecca J. Clark,^{a*} Laura V. Ashton,^a Mark J. Delorey,^a Claudia R. Molins^a

TABLE 1 Results of first-tier tests, MTTTs, and STTTs

	Tes									
		First-tier te	First-tier test		MTTT algo	orithm		STTT algorithm ^b		
Sample type	No. of samples	VIsE	C6	WCS	VlsE/C6	WCS/C6	WCS/VIsE	VlsE/ ViraStripe	C6/ ViraStripe	WCS/ ViraStripe
Lyme disease	124									
Early Lyme disease with EM ^c										
Acute phase	40	23 (58)	23 (58)	29 (73)	20 (50)	22 (55)	23 (58)	17 (43)	17 (43)	20 (50)
Convalescent phase	38	30 (79)	32 (84)	35 (92)	29 (76)	30 (79)	29 (76)	23 (61)	23 (61)	24 (63)
Early Lyme neuroborreliosis or Lyme carditis										
Lyme neuroborreliosis	10	10 (100)	10 (100)	10 (100)	10 (100)	10 (100)	10 (100)	9 (90)	9 (90)	9 (90)
Lyme carditis	7	5 (71)	6 (86)	7 (100)	5 (71)	6 (86)	5 (71)	5 (71)	6 (86)	7 (100)
Late Lyme disease										
Lyme arthritis	29	29 (100)	29 (100)	29 (100)	29 (100)	29 (100)	29 (100)	28 (97)	28 (97)	28 (97)
Total for Lyme disease		97 (78)	100 (81)	110 (89)	93 (75)	97 (78)	96 (77)	82 (66)	83 (67)	88 (71)
Controls	347									
Other diseases	144									
Fibromyalgia	31	0 (0)	0 (0)	9 (29)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Severe periodontitis	20	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Rheumatoid arthritis	21	0 (0)	0 (0)	9 (43)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Syphilis	20	2 (10)	2 (10)	18 (90)	0 (0)	2 (10)	2 (10)	0 (0)	1 (5)	0 (0)
Multiple sclerosis	22	0 (0)	1 (5)	8 (36)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	0 (0)
Infectious mononucleosis	30	1 (3)	4 (13)	19 (63)	0 (0)	2 (7)	1 (3)	0 (0)	1 (3)	9 (30)
Total for other diseases		3 (2)	7 (5)	64 (44)	0 (0)	5 (3)	3 (2)	0 (0)	2 (1)	9 (6)
Healthy controls	203									
Region of endemicity	101	3 (3)	1 (1)	24 (24)	1 (1)	1 (1)	1 (1)	1 (1)	1 (1)	5 (5)
Region of nonendemicity	102	1 (1)	4 (4)	23 (23)	1 (1)	2 (2)	0 (0)	0 (0)	1 (1)	1 (1)
Total for healthy controls		4 (2)	5 (2)	47 (23)	2 (1)	3 (1)	1 (0)	1 (0)	2 (1)	6 (3)
Total for negative controls		7 (2)	12 (3)	111 (32)	2 (1)	8 (2)	4 (1)	1 (0) ^d	4 (1)	15 (4)

Performance of a Modified Two-Tiered Testing Enzyme Immunoassay Algorithm for Serologic Diagnosis of Lyme Disease in Nova Scotia

lan R. C. Davis,^{a,b,c} Shelly A. McNeil,^{a,b,c} Wanda Allen,^b Donna MacKinnon-Cameron,^b L. Robbin Lindsay,^d Katarina Bernat,^d Antonia Dibernardo,^d Jason J. LeBlanc,^{a,b,c} Todd F. Hatchette^{a,b,c}




FIG 1 Breakdown of LD serological testing and chart review results. PTLDS, posttreatment Lyme disease syndrome. *, three charts had no IB results. **, of the six individuals who had a positive IgM immunoblot but a negative IgG immunoblot, for two symptoms were ongoing for >30 days and one was diagnosed with optic neuritis and ultimately multiple sclerosis, all consistent with false-positive IgM results; of the remaining three, one patient had 3 days of chest pain and no other symptoms (not a typical presentation for LD), one patient had no clinical data associated with the sample, and one patient had 1 week of subjective fever without documentation of temperature but with no other symptoms. ***, two patients with negative IgG IBs did not have IgM tested, as symptoms were ongoing for >30 days.

- Between 2011-2014, 10253 patients were tested using STTT method
- Samples that were WCS EIA positive were also tested for C6 EIA.
- 271 patients with WCS/C6 positive had their charts reviewed
- Patient charts with WCS neg were NOT reviewed – thus can't determine true sensitivity
- MTTT detected 25% more early localized cases than STTT
- Specificity was comparable

Stage	Published	performa	nce of MTT	г	Modeled performance of MTTT*			
	EIA methods	Sn (%)	Sp (%)	Ref.	FN**	TN**	Sp (%) [95% CI]	
	WCS; C6	53	99.5	18	56	9750	99.6 [99.4 to 99.7]	
	WCS; C6	38	99.5		103	9703	99.5 [99.4 to 99.7]	
Early localized	WCS; VIsE	36	99.5		112	9694	99.5 [99.4 to 99.7]	
	VlsE; C6	54	99.3	19	54	9752	99.6 [99.4 to 99.7]	
	WCS; C6	50	98		63	9743	99.6 [99.4 to 99.7]	
	VlsE; C6	48	98		68	9738	99.6 [99.4 to 99.7]	
	WCS; C6	55	98		52	9754	99.6 [99.4 to 99.7]	
	WCS; VIsE	58	99	23	46	9760	99.6 [99.4 to 99.7]	
	VlsE; C6	50	99		63	9743	99.6 [99.4 to 99.7]	
	VlsE/C10; WCS	73	98.9	16	23	9783	99.6 [99.4 to 99.7]	
Early disseminated	WCS; C6	100	99.5	18	0	9806	99.6 [99.4 to 99.7]	
	WCS; C6	88	98	28	8	9798	99.6 [99.4 to 99.7]	
	VlsE; C6	88	98	20	8	9798	99.6 [99.4 to 99.7]	
	WCS; C6	100	98		0	9806	99.6 [99.4 to 99.7]	
	WCS; VIsE	100	99	23	0	9806	99.6 [99.4 to 99.7]	
	VlsE; C6	100	99		0	9806	99.6 [99.4 to 99.7]	
	VlsE/C10; WCS	66.1	98.9	16	31	9775	99.6 [99.4 to 99.7]	
	WCS; C6	100	99.5	18	0	9806	99.6 [99.4 to 99.7]	
	WCS; C6	100	98	28	0	9806	99.6 [99.4 to 99.7]	
	VlsE; C6	100	98	20	0	9806	99.6 [99.4 to 99.7]	
Late disseminated	WCS; C6	100	98		0	9806	99.6 [99.4 to 99.7]	
	WCS; VIsE	100	99	23	0	9806	99.6 [99.4 to 99.7]	
	VlsE; C6	100	99		0	9806	99.6 [99.4 to 99.7]	
	VlsE/C10; WCS	100	98.9	16	0	9806	99.6 [99.4 to 99.7]	
	WCS; C6	68	99.5	18	107	9699	99.5 [99.4 to 99.7]	
	WCS; C6	76	98	28	72	9734	99.6 [99.4 to 99.7]	
All patients	VlsE; C6	73	98	20	84	9722	99.6 [99.4 to 99.7]	
combined	WCS/C6	78	98		64	9742	99.6 [99.4 to 99.7]	
comsined	WCS/VIsE	77	99	23	68	9738	99.6 [99.4 to 99.7]	
	VIsE/C6	75	99		76	9730	99.6 [99.4 to 99.7]	
	VlsE/C10; WCS	81	98.9	16	53	9753	99.6 [99.4 to 99.7]	

Estimation of MTTT specificity in Nova Scotia patients of whom charts were reviewed

Table 2. Sensitivity of standard and modified serological testing for Lyme disease in patients with LD

			STTT sensitivity	MTTT ⁵ sensitivity %
Reference (sample size)	Disease manifestations ¹	2 EIAs combinations used ²	(CI) ⁴	(CI)
Branda et al. 2011 (140)	EM, ENB, LC	WCS f/b C6	48 (40-56)	61 (53-69)
Branda et al. 2018 (318)	EM, ENB	WCS f/b C6	41 (36-46)	60 (55-66)
		WCS f/b C6; WCS f/b VIsE CFLIA; VIsE FLIA f/b		
Branda et al. 2017 (55)	Acute EM	C6	25	38; 36; 54
		WCS f/b C6; WCS f/b VIsE CFLIA; VIsE FLIA f/b		
Branda et al. 2017 (47)	Convalescent EM	C6	55	72; 66; 72
Maline at al. 2016 (OF)		Video f/b CC or VIoF3		
Molins et al. 2016 (95)	EM, ENB, LC	Vidas f/b C6 or VIsE ³	60.2 (56.8-64.2)*	66.8 (65.2-68.4) ³
Lipsett et al. 2016 (114)	All disease stages combined	WCS f/b C6	81.6 (73-88)	79.8 (71.1-86.5)
Pegalajar-Jurado et al. 2018				
(40)	Acute EM	VIsE f/b C6; WCS f/b C6; WCS f/b VIsE	43; 43; 50**	50; 55; 58
Pegalajar-Jurado et al. 2018				
(38)	Convalescent EM	VIsE f/b C6; WCS f/b C6; WCS f/b VIsE	61; 61; 63	76; 79; 76
Pegalajar-Jurado et al. 2018				
(124)	All disease stages combined	VIsE f/b C6; WCS f/b C6; WCS f/b VIsE	66, 67; 71	75: 78: 77
Zweitzig et al. 2019 (30)	Acute EM	VIsE /PEPC10 f/b WCS	50	73.3
Zweitzig et al. 2019 (30)	Convalescent EM	VIsE /PEPC10 f/b WCS	76.7	83.3
	Early disseminated disease-stage			
Zweitzig et al. 2019 (56)	2	VIsE /PEPC10 f/b WCS	60.7	66.1
Branda et al. 2011 (29)	LA, LNB	WCS f/b C6	100 (86-100)	100 (86-100)
Branda et al. 2018 (122)	LA, LNB	WCS f/b C6	96 (91-98)	98 (93-99)
Molins et al. 2016 (29)	LA	Vidas f/b C6 or VIsE ³	98.9 (97-100)	100
	Late disseminated disease-stage			
Zweitzig et al. 2019 (50)	3	VISE /PEPC10 f/b WCS	100	100
Zweitzig et al. 2019 (50)		VIsE /PEPC10 f/b WCS	100	100

Adapted from: Hatchette T, Robbin L; Lyme Disease Diagnostics Working Group. Modified two-tiered testing algorithm for Lyme disease serology: the Canadian context. Can Commun Dis Rep. 2020;46(5):125-31. Available from: https://doi.org/10.14745/ccdr.v46i05a05

Table 3. Specificity of standard and modified serological testing for Lyme disease in control subjects

			MTTT specificity %
Reference (sample size)	Patient cohort	2 EIAs combinations used ¹	(CI)
Overall controls			
Branda et al. 2011 (1300)	Healthy and symptomatic controls	WCS f/b C6	99.5 (98.9-99.8)
	Healthy controls & patients with other		
Branda et al. 2018 (2208)	diseases	WCS f/b C6	99.5 (99.1-99.8)
	Healthy controls & patients with other		
Molins et al. 2016 (347)	diseases	Vidas f/b C6 or VIsE2	98.3 (96.2-99.3)
Lipsett et al. 2016 (931)	Healthy and symptomatic controls	WCS f/b C6	96.5 (94.6-97.6)**
Pegalajar-Jurado et al.	Healthy controls & patients with other		
2018 (347)	diseases	VIsE f/b C6; WCS f/b C6; WCS f/b VIsE	99.4; 97.7; 98.8
	Healthy controls & patients with other		
Zweitzig et al. 2019 (190)	diseases	VIsE /PEPC10 f/b WCS	98.9
Unhealthy controls only			
Branda et al. 2011 (54)	Symptomatic controls	WCS f/b C6	100
		WCS f/b C6; WCS f/b VIsE CLIA; VIsE	
Branda et al. 2017 (50)	Patients with other diseases	CLIAf/b C6	98
Molins et al. 2016 (144)	Patients with other diseases	Vidas f/b C6 or VIsE2	98.2 (96.5 -100)**
Lipsett et al. 2016 (830)	Symptomatic controls	WCS f/b C6	96.5 (94.6-97.6)**
Pegalajar-Jurado et al.			
2018 (144)	Patients with other diseases	VIsE f/b C6; WCS f/b C6; WCS f/b VIsE	100; 96.5; 98
Zweitzig et al. 2019 (90)	Patients with other diseases	VIsE /PEPC10 f/b WCS	97.8

"Science rarely advances by revolution. Science is an activity carried out by hundreds of thousands of researchers all contributing to the general picture that eventually emerges."

Eric Scerii

Historian

U of California at Los Angeles

From New York Times

Advantages and Disadvantages of the MTTT Compared to STTT

Advantages

- Improved sensitivity for the detection of early infection (>25% improvement)
- Less costly
- Less laborious
- Less subjectivity
- Faster TAT

Disadvantages

- Cannot be used to rule out early localized disease (sen: <90%)
- Similar to STTT, MTTT cannot differentiate between recent and past infection or re-infections
- May provide lower specificity in low prevalence area (data unclear)

Recommendations by CDC AND CPHLN

- *"When cleared by FDA for this purpose, serologic assays that utilize EIA rather than western immunoblot assay in a two-test format are acceptable alternatives for the laboratory diagnosis of Lyme disease."*
 - Mead P, Petersen J, Hinckley A. Updated CDC recommendation for serologic diagnosis of Lyme disease. MMWR Morb Mortal Wkly Rep. 2019;68:703. Available from:


- *"Our working group agrees with the recommendation by the United States Centers for Disease Control that serological testing for LD using MTTT is an acceptable alternative to STTT."*
 - Hachette T, Lindsay R; Lyme Disease Diagnostics Working Group. Modified two-tiered testing algorithm for Lyme disease serology: the Canadian context. Can Comm Dis Rep. 2020;46(5):125-31. Available from:

IDSA draft statement: https://www.idsociety.org/practice-guideline/lyme-disease/

- Serological testing for Lyme Disease
 - "Serum antibody tests should be performed using clinically validated assays in a conventional 2-tiered testing protocol, in which an enzyme immunoassay (EIA) or indirect fluorescent antibody test (IFA) is followed by immunoglobulin M (IgM) and IgG immunoblots, or in a modified 2-tiered testing protocol, in which 2 different EIAs are performed sequentially or concurrently without the use of immunoblots [23–27]."

Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, Auwaerter PG, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of Lyme disease. Clin Infect Dis. 2021;72(1):e1-48. Available from:

As of April 1, 2023, PHO is Implementing Modified-two Tier-testing (MTTT)



Testing Indications

- Serological testing of asymptomatic patients, including individuals following a tick bite, is not recommended.
- Serological testing for individuals with Erythema migrans, acute phase (seasonal occurrence and exposure in an endemic/risk area) is **generally not recommended.**
- Serological testing is useful for individuals in the absence of a rash, presenting with non-specific symptoms where Lyme disease is suspected. An acute and convalescent specimen (2-4 weeks apart) may be required for laboratory confirmation of Lyme disease.
- Serological tests should **not** be used to assess treatment response.
- When European Lyme is suspected, European Lyme serology should be specifically stated on the requisition along with exposure to tick bite and RECENT travel history (≤ 12 months) including location and dates

Lyme Disease Test Result Interpretation

Lyme Tier 1 EIA	Lyme Tier 2 EIA	Borrelia burgdorferi (Lyme disease) serology interpretation
Non- Reactive	Not tested	Non- Reactive
		Advise follow-up specimen (2-4 weeks apart) if clinically indicated.
Indeterminate	Non- Reactive	Non- Reactive
		The results should be interpreted within the clinical context.
		Advise follow-up specimen (2-4 weeks apart) if clinically indicated.
Indeterminate	Indeterminate	Indeterminate
		The results should be interpreted within the clinical context.
		Advise follow-up specimen (2-4 weeks apart) if clinically indicated.
		Copy of results sent to MOH.
Indeterminate	Reactive	Reactive
		The results should be interpreted within the clinical context.
		Copy of results sent to MOH.
Reactive	Non- Reactive	Non- Reactive
		The results should be interpreted within the clinical context.
		Advise follow-up specimen (2-4 weeks apart) if clinically indicated.
Reactive	Indeterminate	Reactive
		The results should be interpreted within the clinical context.
		Copy of results sent to MOH.
Reactive	Reactive	Reactive
		The results should be interpreted within the clinical context.
		Copy of results sent to MOH.

Lyme Disease Serological Testing Changes: Implications for Practice

Testing Changes: Implications for Practice

- Potential for more early cases identified
- Diagnosis of early localized Lyme disease is still a <u>clinical diagnosis</u>
- Minimal changes to interpretation of results
 - Lyme disease test information sheet: results interpretation
- Minimal changes to iPHIS case entry
 - Updated Lyme disease Ontario Investigation Tool (OIT)
- Updated Ontario Health Clinical Guidance Document
 - Management of Tick Bites and Investigation of Early Localized Lyme Disease
- Updated Ministry of Health Appendix 1: Lyme Disease

Ontario Investigation Tool Updates

Human Lab Testing Information									
Requisition #	Test Date	Sample Type (serum)	Collection Date	EIA/ELIS A Result IgM/IgG	Western Blot IgM	Western Blot IgG	Results		
	YYYY-MM-DD		YYYY-MM-DD				 Reactive Non-Reactive Indeterminate 		

OLD

NEW


Human Lab Testi	ng Information						
Requisition #	Test Date	Sample Type (serum)	Collection Date	EIA/ELISA T 1 Result IgM/IgG	2	/ELISA Tier 2 Result gM/IgG	Results
	YYYY-MM-DD		YYYY-MM-DD				 Reactive Non-Reactive Indeterminate
European Humar	n Lab Testing Inf	ormation				,	
Travel to Europe		□ YES, if ye	s please fill out th	ne following in	nformation		

Source: Ontario Agency for Health Protection and Promotion (Public Health Ontario). Lyme disease investigation tool [Internet]. Toronto, ON: King's Printer for Ontario; 2023 [cited 2023 Apr 13]. Available from:

CLINICAL GUIDANCE DOCUMENT

Management of Tick Bites and Investigation of Early Localized Lyme Disease

Please contact us at evidence@ontariohealth.ca or 1-877-280-8538 if you have any questions or feedback about this clinical guidance document.



Source: Health Quality Ontario. Clinical guidance document: management of tick bites and investigation of early localized Lyme disease. Toronto, ON: King's Printer for Ontario; 2023. Available from:

Box 1. Clinical Manifestations of Early Localized Lyme Disease: Erythema Migrans Rashes



Box 2. Prevalence of Symptoms in Patients Presenting With Possible Early Localized Lyme Disease*

- Erythema migrans rash (typical or atypical) ~70%
 Fever/chills 39%
- Fatigue 54%
- Myalgia 44%

Decreased appetite 26%

Stiff neck 35%

*As a disease of public health significance, Lyme disease is reportable in Ontario under the Health Protection and Promotion Act, R.S.O. 1990, c. H.7.

Box 4. Areas of Risk for Lyme Disease

- The risk of acquiring Lyme disease varies across geographical regions. Please click to see the risks in <u>Ontario, Canada</u>, and the <u>United States</u>
- In Europe, the areas of highest risk are in Central and Eastern Europe, but infected ticks have also been found in Southern Scandinavia and up to the northern Mediterranean region

Box 5. Post-Exposure Prophylaxis

The risk of developing Lyme disease following a tick bite by an infected tick is between 1% and 3%. In Ontario, the prevalence of infected ticks varies by geographic region. In many instances, it is reasonable to adopt the "wait and see" approach and treat patients if they develop symptoms compatible with Lyme disease. Counsel patients to watch for the development of early signs and symptoms for 30 days, and advise patients that other tick-borne infections may result in signs or symptoms too.


Based on the best available evidence, post-exposure prophylaxis can be considered if these four criteria are met:


- 1. The tick was attached > 24 hours
- 2. The tick was removed within the past 72 hours
- The tick was acquired in an area with a prevalence of ticks infected with *Borrelia burgdorferi* > 20% (e.g., Rouge National Urban Park and Morningside Park in the Greater Toronto

Additional images of typical and atypical rashes are available on <u>Health Canada's</u> <u>website</u>; under "Clinical manifestations," please see "Erythema migrans rash."

Note: People with darker skin tones may present with a bruise-like rash.

Box 3. Blacklegged Ticks at Various Stages and Safe Tick Removal





Area, Brighton, Kingston and surrounding areas, Thousand Islands, Brockville, Perth-Smiths Falls and surrounding areas, Ottawa and surrounding areas, Rondeau Provincial Park in Morpeth, and Pinery Provincial Park in Grand Bend*)

 Doxycycline is not contraindicated. (Doxycycline is contraindicated for pregnant or lactating people and those with an allergy. There is insufficient evidence for the prophylactic use of other medications, such as amoxicillin)

Recommended treatment for post-exposure prophylaxis:

Adults: 1 dose of doxycycline 200 mg, by mouth

Children < 18 years of age: 1 dose of doxycycline 200 mg dose or 4 mg/kg (up to a maximum dose of 200mg), by mouth

*Note: This is not a comprehensive list of higher-risk areas in Ontario. Infectivity rate is not uniformly collected and updated, and therefore postexposure prophylaxis decisions are sometimes made based on risk-benefit discussions with patients.

For more information, please refer to the Ontario Lyme Disease Map.

Box 6. Laboratory Testing

- Laboratory testing is generally not indicated for asymptomatic patients
- Serological testing may not yield positive results during early localized Lyme disease, so management should not be based on serological testing results during this phase
- Antibiotic treatment in early disease may reduce seroconversion; testing should not be used to monitor treatment outcome
- Following exposure to *Borrelia burgdorferi*, immunoglobulin M (IgM) antibodies are detected within 2–4 weeks, and IgG antibodies within 4–6 weeks
- As of April 1, 2023, Public Health Ontario uses a modified two-tiered testing (MTTT) algorithm to maximize sensitivity and specificity (see Box 7)
- For serological testing, please complete the <u>requisition</u> fully and submit it, along with samples, to a public health laboratory for testing
- If European Lyme disease is suspected based on the patient's travel history, please order serology testing

rythema migrans, acute phase early localized disease)	58%
Trythema migrans, convalescence phase [‡] early localized disease)	76%
Neurological involvement (early disseminated disease)	100%
Arthritis (late disseminated disease)	100%
he MTTT algorithm is based on serum sample ini sing IgG/IgM enzyme-linked immunosorbent assa hole cell lysate (tier 1). If results of tier 1 ELISA re determinate, sample is further tested using secor ISA assay targeting specifically VISE1 and pepC	ly (ELISA) using sults are reactiv nd (tier 2) IgG/Ig

Box 7. Sensitivity of Serological (Modified Two-

*Following antibiotic treatment.

Box 8	3. Recommendations	for Treatmen	t of Patients	With Early Lo	ocalized Lyme D	isease

Drugs	Dosage for Adults	Dosage for Children
Preferred		
Doxycycline*	100 mg twice a day for 10−21 days [†] Contraindicated for pregnant or lactating people	For children < 18 years of age: 4 mg/kg, orally divided into 2 doses (maximum 200 mg/day) for 10-21 days [†]
Amoxicillin	500 mg three times a day for 14–21 days	For children < 18 years of age: 50 mg/kg/day orally, divided into 3 equal doses per day, maximum of 500 mg per dose for 14–21 days
Cefuroxime	500 mg twice per day for 14–21 days	For children > 8 years of age: 30 mg/kg/day divided in 2 doses (maximum 500 mg/ dose) for 14–21 days
For Allergy or Int	olerance [‡]	
Azithromycin	500 mg/day for 7–17 days	For children < 18 years of age: 10 mg/kg/day, orally, once daily for 7–17 days
Clarithromycin	500 mg twice a day for 14–21 days Relatively contraindicated in pregnant people	For children > 8 years of age: 7.5 mg/kg twice a day (maximum 500 mg/day) for 14–21 days

Source: Health Quality Ontario. Clinical guidance document: management of tick bites and investigation of early localized Lyme disease. Toronto, ON: King's Printer for Ontario; 2023. Available from:

Summary

- Effective Apr 1, 2023 PHO implemented modified two-tier testing (MTTT) for detection of antibodies against *B. burgdorferi* (Lyme Disease)
- The MTTT algorithm has been endorsed by the Centers for Disease Control and Prevention (CDC) as well as the Canadian Public Health Laboratory Network (CPHLN) as an acceptable alternative method to the standard two-tier testing (STTT)
- Sensitivity of MTTT is higher (15-25%) than STTT in detecting antibodies during early-localized Lyme disease
- PHO has updated iPHIS and the Lyme disease OIT to meet the new testing updates

Links

•

- Lyme Disease Ontario Investigation Tool
- Lyme Disease Test Information Sheet
- Ontario Lyme Disease Estimated Risk Areas Map

- Ontario Health Clinical Guidance Document: Management of Tick Bites and Investigation of Early Localized Lyme Disease
- Ministry of Health Appendix 1: Lyme Disease



Case #1

- 68-year-old retired nurse living in Ottawa area was bitten by a tick while gardening
- She took the tick to her local public health unit, but the tick was not sent to the laboratory at Public Health Ontario for identification
- A few days later she developed a rash and "flu-like" symptoms
- Upon examination erythematous rash at the site of the bite measuring 8 cm
- Treated with doxycycline for two weeks
- Doctor did not test her for Lyme disease antibodies

Case #1 Questions

- What evidence supports the diagnosis of early localized Lyme disease?
- Should the physician have ordered serology?
- Patient returns and insists on getting tested for Lyme disease.
 How would you counsel her?


Case #1 Questions

- What evidence supports the diagnosis of early localized Lyme disease?
- Should the physician have ordered serology?
- Patient returns and insists on getting tested for Lyme disease.
 How would you counsel her?


CLINICAL GUIDANCE DOCUMENT

Management of Tick Bites and Investigation of Early Localized Lyme Disease

Please contact us at **evidence@ontariohealth.ca** or **1-877-280-8538** if you have any questions or feedback about this clinical guidance document.



Source: Health Quality Ontario. Clinical guidance document: management of tick bites and investigation of early localized Lyme disease. Toronto, ON: King's Printer for Ontario; 2023. Available from:



Source: Health Quality Ontario. Clinical guidance document: management of tick bites and investigation of early localized Lyme disease. Toronto, ON: King's Printer for Ontario; 2023. Available from:

Case #1 Questions

- What evidence supports the diagnosis of early localized Lyme disease?
- Should the physician have ordered serology?
- Patient returns and insists on getting tested for Lyme disease.
 How would you counsel her?

Box 1. Clinical Manifestations of Early Localized Lyme Disease: Erythema Migrans Rashes



Headache 42%

Fever/chills 39%

Box 2. Prevalence of Symptoms in Patients Presenting With Possible Early Localized Lyme Disease*

- Erythema migrans rash (typical or atypical) ~70%
- Fatigue 54%
- Myalgia 44%

Stiff neck 35%Decreased appetite 26%

*As a disease of public health significance, Lyme disease is reportable in Ontario under the Health Protection and Promotion Act, R.S.O. 1990, c. H.7.

Box 4. Areas of Risk for Lyme Disease

- The risk of acquiring Lyme disease varies across geographical regions. Please click to see the risks in <u>Ontario, Canada</u>, and the <u>United States</u>
- In Europe, the areas of highest risk are in Central and Eastern Europe, but infected ticks have also been found in Southern Scandinavia and up to the northern Mediterranean region

Box 5. Post-Exposure Prophylaxis

The risk of developing Lyme disease following a tick bite by an infected tick is between 1% and 3%. In Ontario, the prevalence of infected ticks varies by geographic region. In many instances, it is reasonable to adopt the "wait and see" approach and treat patients if they develop symptoms compatible with Lyme disease. Counsel patients to watch for the development of early signs and symptoms for 30 days, and advise patients that other tick-borne infections may result in signs or symptoms too.


Based on the best available evidence, post-exposure prophylaxis can be considered if these four criteria are met:


- 1. The tick was attached > 24 hours
- 2. The tick was removed within the past 72 hours
- The tick was acquired in an area with a prevalence of ticks infected with *Borrelia burgdorferi* > 20% (e.g., Rouge National Urban Park and Morningside Park in the Greater Toronto

Additional images of typical and atypical rashes are available on <u>Health Canada's</u> <u>website</u>; under "Clinical manifestations," please see "Erythema migrans rash."

Note: People with darker skin tones may present with a bruise-like rash.

Box 3. Blacklegged Ticks at Various Stages and Safe Tick Removal





Area, Brighton, Kingston and surrounding areas, Thousand Islands, Brockville, Perth-Smiths Falls and surrounding areas, Ottawa and surrounding areas, Rondeau Provincial Park in Morpeth, and Pinery Provincial Park in Grand Bend*)

 Doxycycline is not contraindicated. (Doxycycline is contraindicated for pregnant or lactating people and those with an allergy. There is insufficient evidence for the prophylactic use of other medications, such as amoxicillin)

Recommended treatment for post-exposure prophylaxis:

Adults: 1 dose of doxycycline 200 mg, by mouth

Children < 18 years of age: 1 dose of doxycycline 200 mg dose or 4 mg/kg (up to a maximum dose of 200mg), by mouth

*Note: This is not a comprehensive list of higher-risk areas in Ontario. Infectivity rate is not uniformly collected and updated, and therefore postexposure prophylaxis decisions are sometimes made based on risk-benefit discussions with patients.

For more information, please refer to the Ontario Lyme Disease Map

Box 6. Laboratory Testing

- Laboratory testing is generally not indicated for asymptomatic patients
- Serological testing may not yield positive results during early localized Lyme disease, so management should not be based on serological testing results during this phase
- Antibiotic treatment in early disease may reduce seroconversion; testing should not be used to monitor treatment outcome
- Following exposure to Borrelia burgdorferi, immunoglobulin M (IgM) and the detected within 2 - the inclusion of antibodies within 4-6 weeks
- As of April 1, 2023, Public Health Ontario uses a modified two-tiered testing (MTTT) algorithm to maximize semilivity and specificity (see Box 7)
- For serological testing, please complete the requisition fully and submit it, along with samples, to a public health laboratory for testing
- If European Lyme disease is suspected based on the patient's travel history, please order serology testing

Box 7. Sensitivity of Serological (Modified Two-Tier) Testing[†] in Patients With Lyme Disease^{6,7} 58% Erythema migrans, acute phase (early localized disease) Erythema migrans, convalescence phase[‡] 76% (early localized disease) 100% Neurological involvement (early disseminated disease) Arthritis (late disseminated disease) 100% [†]The MTTT algorithm is based on serum sample initially tested using IgG/IgM enzyme-linked immunosorbent assay (ELISA) using a whole cell lysate (tier 1). If results of tier 1 ELISA results are reactive/ indeterminate, sample is further tested using second (tier 2) IgG/IgM

ELISA assay targeting specifically VIsE1 and pepC10 antigens.

*Following antibiotic treatment.

Box 8. Recommendations for Treatment of Patients With Early Localized Lyme Disease

Drugs	Dosage for Adults	Dosage for Children
Preferred		
Doxycycline*	100 mg twice a day for 10–21 days†	For children < 18 years of age: 4 mg/kg, orally divided into 2 doses (maximum 200 mg/day) for 10-21 days [†]
	Contraindicated for pregnant or lactating people	
Amoxicillin	500 mg three times a day for 14–21 days	For children < 18 years of age: 50 mg/kg/day orally, divided into 3 equal doses per day, maximum of 500 mg per dose for 14–21 days
Cefuroxime	500 mg twice per day for 14–21 days	For children > 8 years of age: 30 mg/kg/day divided in 2 doses (maximum 500 mg/ dose) for 14–21 days
For Allergy or Int	olerance [‡]	
Azithromycin	500 mg/day for 7–17 days	For children < 18 years of age: 10 mg/kg/day, orally, once daily for 7–17 days
Clarithromycin	500 mg twice a day for 14-21 days	For children > 8 years of age: 7.5 mg/kg twice a day (maximum 500 mg/day) for 14–21 days
	Relatively contraindicated in pregnant people	

Source: Source: Health Quality Ontario. Clinical guidance document: management of tick bites and investigation of early localized Lyme disease. Toronto, ON: King's Printer for Ontario; 2023. Available from:


Case #2

- 19 year old student lives in Kitchener
- Presented to a doctor with a 1 week history of rash (circular erythematous patch)
- General "flu-like" symptoms (i.e., fatigue, chills, fever, headache, muscle and joint aches, and swollen lymph nodes)
- No travel history to risk areas and no possible contact with ticks in past month
- Initial thoughts and work-up?


CLINICAL GUIDANCE DOCUMENT

Management of Tick Bites and Investigation of Early Localized Lyme Disease

Please contact us at **evidence@ontariohealth.ca** or **1-877-280-8538** if you have any questions or feedback about this clinical guidance document.



Source: Health Quality Ontario. Clinical guidance document: management of tick bites and investigation of early localized Lyme disease. Toronto, ON: King's Printer for Ontario; 2023. Available from:




Source: Ontario Agency for Health Protection and Promotion (Public Health Ontario). Ontario Lyme disease map 2022 estimated risk areas [Internet]. Toronto, ON: Queen's Printer for Ontario; 2022 [cited 2023 Apr 6]. Available from:

CLINICAL GUIDANCE DOCUMENT

Management of Tick Bites and Investigation of Early Localized Lyme Disease

Please contact us at evidence@ontariohealth.ca or 1-877-280-8538 if you have any questions or feedback about this clinical guidance document.



Source: Health Quality Ontario. Clinical guidance document: management of tick bites and investigation of early localized Lyme disease. Toronto, ON: King's Printer for Ontario; 2023. Available from:

Questions?

Acknowledgements

- Mark Nelder, Senior Program Specialist, Enteric, Zoonotic, Vector-Borne Diseases, Public Health Ontario
- Curtis Russell, Senior Program Specialist, Enteric, Zoonotic, Vector-Borne Diseases, Public Health Ontario

For More Information About This Presentation, Contact:

Public Health Ontario keeps Ontarians safe and healthy. Find out more at **PublicHealthOntario.ca**



Links

- Ontario Agency for Health Protection and Promotion (Public Health Ontario). Lyme disease investigation tool [Internet]. Toronto, ON: King's Printer for Ontario; 2023 [updated 2023 Apr 3; cited 2023 Apr 13]. Available from:
- Ontario Agency for Health Protection and Promotion (Public Health Ontario). Test information index [Internet]. Toronto, ON: King's Printer for Ontario; 2023 [cited 2023 Apr 13]. Available from:
- Ontario Agency for Health Protection and Promotion (Public Health Ontario). Lyme disease [Internet]. Toronto, ON: King's Printer for Ontario; 2023 [cited 2023 Apr 13]. Available from:
- Health Quality Ontario. Guidance document: Lyme disease [Internet]. Toronto, ON: King's Printer for Ontario [cited 2023 Apr 13]. Available from:
- Ontario. Ministry of Health. Ontario public health standards. Infectious disease protocol. Appendix 1: case definitions and disease-specific information. Disease: Lyme disease. Effective: April 2023 [Internet]. Toronto, ON: Queen's Printer for Ontario; 2023 [cited 2023 Apr 13]. Available from: